RxDoctor Payments Data

Gregory Albers, MD

Vascular Neurology · Stanford, CANPI 1205889698

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $382,870 of the $414,856 with a category attached, or 92.3%. 24 manufacturers reported payments, led by Genentech, Inc. at 39.3% of the total. Reporting peaked in 2019 at $121,281 and has fallen 59.2% since, to $49,526 in 2025. Among vascular neurology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$414,856in general payments, 2019–2025

Across 83 payments — averaging $4998.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$163K
  • Ischemaview, Inc.$160K
  • F. Hoffmann-la Roche AG$20K
  • Astrazeneca UK Limited$15K
  • Portola Pharmaceuticals, LLC$8K
  • Bayer$7K
  • plus $42K from 18 others
$7,139in research payments, 2019–2025

Across 6 payments — averaging $1189.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biogen$5K
  • F. Hoffmann-la Roche AG$2K

What the payments were for

  • Consulting fees$382,87092%
  • Speaking & faculty fees$6,7672%
  • Travel & lodging$23,1966%
  • Food & beverage$2,0240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$414,856 in reported general payments places this provider in the 95th percentile of 58 vascular neurology providers in California.

See all vascular neurology providers in California

Medicare billing

Part B allowed, 2024
$14,824
Medicare patients
62
Services billed
96

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other vascular neurology in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →